Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

Rhea-AI Summary

Rain Therapeutics (NasdaqGS: RAIN) has announced its participation in Citi’s 17th Annual BioPharma Conference, scheduled for September 7-8, 2022, at the Four Seasons Hotel, Boston, MA. CEO Avanish Vellanki will be part of a targeted oncology panel on September 8 from 2:40-3:25 PM ET. The company focuses on developing precision oncology therapies, including milademetan, a small molecule inhibitor of the MDM2-p53 complex, which reactivates p53. Rain emphasizes a tumor-agnostic strategy to select patients based on genetic profiles.

NEWARK, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that company management will be participating in Citi’s 17^th Annual BioPharma Conference on September 7-8, 2022 taking place at the Four Seasons Hotel in Boston, MA.

Company management will participate in one-on-one investor meetings, and Avanish Vellanki, CEO, will be participating in a company panel for targeted oncology on Thursday, September 8 at 2:40-3:25 PM ET. The webcast of the panel is linked here.

If you would like to request a meeting with management, please contact your Citi representative.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

What is Rain Therapeutics' participation in the Citi BioPharma Conference?

Rain Therapeutics will participate in Citi’s 17th Annual BioPharma Conference on September 7-8, 2022.

When is Avanish Vellanki speaking at the conference?

Avanish Vellanki will speak on September 8, 2022, from 2:40-3:25 PM ET.

What is the lead product of Rain Therapeutics?

Rain's lead product candidate is milademetan, an oral inhibitor targeting the MDM2-p53 complex.

What unique approach does Rain Therapeutics use for patient selection?

Rain employs a tumor-agnostic strategy, selecting patients based on their tumors' genetic profiles.

Where is the Citi BioPharma Conference being held?

The conference is being held at the Four Seasons Hotel in Boston, MA.